Hospital
Central Florida Regional Hospital, INC
Central Florida Regional Hospital, INC was paid $7.32M by Medicaid between Jan 2018 and Dec 2024, across 146 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoCENTRAL FLORIDA REGIONAL HOSPITAL, INC
SANFORD, FL 32771
SANFORD, FL 32771
33aNPI1285681908assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.32M
24GClaims367,944
24DCodes billed146
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#67 of 163
Median peer was paid$4.77M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,612 | $238K | |
| 2019 | 96,340 | $984K | |
| 2020 | 64,724 | $801K | |
| 2021 | 73,451 | $1.64M | |
| 2022 | 69,578 | $2.05M | |
| 2023 | 25,575 | $1.14M | |
| 2024incomplete | 7,664 | $478K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 27,744 | 25,292 | $2.12M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 21,391 | 18,496 | $1.29M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.8% | 4,307 | 3,704 | $423K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.0% | 2,555 | 2,345 | $366K |
| 80053 | Comprehensive metabolic panel | 4.5% | 17,723 | 13,638 | $328K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 4,750 | 4,000 | $323K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.3% | 4,367 | 4,032 | $318K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.7% | 7,275 | 6,138 | $268K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 1,748 | 1,532 | $217K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.0% | 6,193 | 5,622 | $145K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 1,331 | 1,180 | $137K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.8% | 1,035 | 912 | $130K |
134 more codes
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 1.6% | 7,155 | $117K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 1,131 | $106K |
| 87070 | 1.0% | 5,492 | $77K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 785 | $64K |
| 84702 | <1% | 7,462 | $51K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,071 | $50K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 550 | $40K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 729 | $36K |
| G0378 | Hospital observation service, per hour | <1% | 4,347 | $36K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 868 | $34K |
| 86850 | <1% | 887 | $34K | |
| A9270 | Non-covered item or service | <1% | 7,230 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,522 | $32K |
| 72131 | <1% | 899 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,004 | $31K |
| 85027 | <1% | 26,662 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,687 | $30K |
| 81003 | <1% | 11,126 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,241 | $22K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,959 | $22K |
| 87280 | <1% | 2,101 | $21K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,109 | $19K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 977 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,809 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,007 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 742 | $15K |
| 87430 | <1% | 6,346 | $15K | |
| 81025 | <1% | 3,638 | $13K | |
| 73610 | <1% | 779 | $12K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,347 | $11K |
| 76801 | <1% | 1,109 | $11K | |
| 73630 | <1% | 945 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 621 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,472 | $10K |
| 73030 | <1% | 605 | $9K | |
| 86900 | <1% | 2,013 | $9K | |
| 81001 | <1% | 4,407 | $9K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,918 | $9K |
| 73562 | <1% | 567 | $9K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,070 | $8K |
| 76830 | Ultrasound, transvaginal | <1% | 733 | $8K |
| 73130 | <1% | 522 | $8K | |
| 93971 | <1% | 494 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 571 | $5K |
| 85610 | <1% | 7,825 | $5K | |
| 85730 | <1% | 6,510 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,343 | $4K |
| 87040 | <1% | 2,046 | $4K | |
| 86901 | <1% | 1,965 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,433 | $3K |
| 72128 | <1% | 205 | $3K | |
| 70486 | <1% | 125 | $3K | |
| 73590 | <1% | 156 | $2K | |
| 83735 | <1% | 7,341 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 716 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 553 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 105 | $2K |
| 84484 | <1% | 7,119 | $2K | |
| 83880 | <1% | 2,419 | $2K | |
| 74022 | <1% | 217 | $2K | |
| 80076 | <1% | 3,191 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,044 | $2K |
| 72100 | <1% | 214 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,354 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 793 | $1K |
| 84100 | <1% | 2,512 | $1K | |
| 29125 | <1% | 57 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,902 | $1K |
| 73110 | <1% | 154 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 29 | $980.52 |
| 72170 | <1% | 87 | $964.93 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,003 | $745.46 |
| 83690 | <1% | 5,734 | $734.70 | |
| 93017 | <1% | 12 | $693.42 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 705 | $679.84 |
| 74018 | <1% | 13 | $664.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,600 | $646.54 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,481 | $626.82 |
| 12001 | <1% | 15 | $587.40 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,530 | $584.37 |
| 93970 | <1% | 90 | $583.20 | |
| 74019 | <1% | 66 | $551.59 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 470 | $540.34 |
| 80061 | Lipid panel | <1% | 719 | $420.85 |
| 73090 | <1% | 66 | $375.93 | |
| 82550 | <1% | 1,388 | $374.26 | |
| 73502 | <1% | 27 | $346.45 | |
| 85378 | <1% | 1,179 | $300.61 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,312 | $286.47 |
| 71250 | <1% | 65 | $280.23 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,790 | $278.71 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,825 | $272.41 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,057 | $239.49 |
| J2704 | Injection, propofol, 10 mg | <1% | 18 | $233.56 |
| 83605 | <1% | 1,067 | $220.95 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 82 | $217.89 |
| 82077 | <1% | 610 | $209.79 | |
| 82248 | <1% | 530 | $209.58 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,296 | $183.19 |
| 85652 | <1% | 29 | $182.77 | |
| 73552 | <1% | 13 | $174.38 | |
| 87186 | <1% | 1,123 | $156.33 | |
| 73564 | <1% | 15 | $102.36 | |
| 87081 | <1% | 77 | $52.31 | |
| 80320 | <1% | 363 | $33.36 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 795 | $32.03 |
| 82553 | <1% | 341 | $30.57 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 205 | $21.72 |
| 80329 | <1% | 33 | $16.84 | |
| 87400 | <1% | 122 | $9.89 | |
| 87147 | <1% | 86 | $1.64 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 207 | $0.00 |
| 80143 | 0% | 103 | $0.00 | |
| 80179 | 0% | 109 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 58 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 134 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 15 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 46 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 45 | $0.00 |
| 73080 | 0% | 41 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 103 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 133 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 77 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 68 | $0.00 |
| C1769 | Guide wire | 0% | 21 | $0.00 |
| 82803 | 0% | 51 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 53 | $0.00 |
| 87205 | 0% | 51 | $0.00 | |
| 96376 | 0% | 30 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 33 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 23 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 14 | $0.00 |
| 94644 | 0% | 15 | $0.00 | |
| 86140 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLANDRY, CHRISTOPHER (CFO)
| Provider | Location | Paid |
|---|---|---|
| Northern Virginia Community Hospital LLC | Dulles, VA | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.